Screener
Syndax Pharmaceuticals SNDX Business Segments — Interest Income Expense Net
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Syndax Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:InterestIncomeExpenseNet.
The source filing: Syndax Pharmaceuticals’s 10-Q, filed April 30, 2026.
- Filed
- Apr 30, 2026, 4:04 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-197154
| March 31, 2026 | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Commercial related expenses | 7,721 | 10,825 |
| Personnel cost and other expenses | 16,701 | 19,082 |
| Other SG&A expenses | 5,140 | 4,412 |
| Stock-based compensation | 12,053 | 10,380 |
| Royalty interest expense | 11,846 | 8,049 |
| Interest expense (income), net | (3,561) | (7,181) |
| Other expense, net | 186 | 221 |
| Segment net loss | $(42,673) | $(84,846) |
Item 1: Financial Statements
FAQ
- What is Syndax Pharmaceuticals's business segments — interest income expense net?
- Syndax Pharmaceuticals (SNDX) reported business segments — interest income expense net of -$3.56M in Q1 2026.
- How has Syndax Pharmaceuticals's business segments — interest income expense net changed year-over-year?
- Syndax Pharmaceuticals's business segments — interest income expense net increased by 50.4% year-over-year, from -$7.18M to -$3.56M.
- What is the long-term trend for Syndax Pharmaceuticals's business segments — interest income expense net?
- Over 3 years (2022 to 2025), Syndax Pharmaceuticals's business segments — interest income expense net has grown at a 58.2% compound annual growth rate (CAGR), from -$2.74M to -$10.83M.
- What does business segments — interest income expense net mean?
- This metric represents the net balance of interest income earned on cash and investment holdings offset by interest expenses incurred on debt obligations within the specific business segment. It reflects the segment's net financing cost or return on capital, providing insight into how the company manages its liquidity and capital structure to support ongoing research and development activities. Monitoring this balance helps investors understand the impact of financial leverage and treasury management on the segment's overall profitability.
Ask your AI about Syndax Pharmaceuticals's business segments — interest income expense net.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude